Empowered Patient Podcast

Dr. Vimal Mehta, CEO and Founder, BioXcel Therapeutics talks about using artificial intelligence approaches in the development of drugs.  BioXcel's two most advanced clinical development programs are (1) BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders like schizophrenia, bipolar disorder, Alzheimer's and opioid addiction and (2) BXCL701, an immuno-oncology agent designed for the treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. BioXCel Therapeutics